ATLANTA, GA — A multicenter controlled trial testing the ability of an aldose reductase inhibitor to stabilize early-stage asymptomatic diabetic cardiomyopathy missed its primary endpoint, researchers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results